CA1
Carbonic anhydrase 1
Also known as: CAH1_HUMAN, Car1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P00915
- Gene
- CA1
- Ensembl
- ENSG00000133742
- Chromosome
- 8
- Canonical length
- 261 aa
- Protein class
- Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
OverviewNCBI Gene
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. This CA1 gene is closely linked to the CA2 and CA3 genes on chromosome 8. It encodes a cytosolic protein that is found at the highest level in erythrocytes. Allelic variants of this gene have been described in some populations. Alternative splicing and the use of alternative promoters results in multiple transcript variants. [provided by RefSeq, Nov 2016]
Canonical amino-acid sequenceUniProt
261 residues, UniProt reviewed canonical sequence.
>P00915|CA1
1 MASPDWGYDD KNGPEQWSKL YPIANGNNQS PVDIKTSETK HDTSLKPISV SYNPATAKEI
61 INVGHSFHVN FEDNDNRSVL KGGPFSDSYR LFQFHFHWGS TNEHGSEHTV DGVKYSAELH
121 VAHWNSAKYS SLAEAASKAD GLAVIGVLMK VGEANPKLQK VLDALQAIKT KGKRAPFTNF
181 DPSTLLPSSL DFWTYPGSLT HPPLYESVTW IICKESISVS SEQLAQFRSL LSNVEGDNAV
241 PMQHNNRPTQ PLKGRTVRAS FLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CA1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 1,982 nTPM
Expression across tissuesHPA
Tissue
- rectum: 1,982 nTPM
- bone marrow: 1,694 nTPM
- colon: 958 nTPM
- spleen: 29 nTPM
- smooth muscle: 29 nTPM
- placenta: 19 nTPM
Single-cell type
- erythrocyte progenitors: 6,551 nCPM
- erythrocytes: 3,491 nCPM
- colonocytes: 2,197 nCPM
- megakaryocyte-erythroid progenitors: 532 nCPM
- enteric transient amplifying cells: 324 nCPM
- epicardial cells: 273 nCPM
Immune cell
- total PBMC: 2.8 nTPM
- memory B-cell: 0.4 nTPM
- plasmacytoid DC: 0.4 nTPM
- classical monocyte: 0.1 nTPM
- myeloid DC: 0.1 nTPM
- naive B-cell: 0.1 nTPM
Brain region
- cerebral cortex: 5.6 nTPM
- cerebellum: 4.6 nTPM
- hypothalamus: 3.8 nTPM
- white matter: 3.8 nTPM
- basal ganglia: 3.3 nTPM
- pons: 3.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CA1.
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 41 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Carbonic anhydrase I, Guam
- Carbonic anhydrase I deficiency
Disease | ImmuneIEDB
Conditions an epitope on CA1 was assayed in.
ReferencesPubMed · IEDB
Publications for CA1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
12 publications
- Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome.
1996 · Gastroenterology · RCR 6.8 · 197 citations - Elevated serum levels of antibodies to carbonic anhydrase I and II in patients with chronic pancreatitis.
2000 · Pancreas · RCR 1.1 · 36 citations - Autoantigenicity of carbonic anhydrase 1 in patients with abdominal aortic aneurysm, revealed by proteomic surveillance.
2013 · Hum Immunol · RCR 0.5 · 17 citations - Spontaneous regression of tumours. Possible cross reactivity of autoantibodies against carbonic anhydrase I.
2023 · J Cell Mol Med · RCR 0.4 · 3 citations - Overlap of epitopes recognized by anti-carbonic anhydrase I IgG in patients with malignancy-related aplastic anemia-like syndrome and in patients with aplastic anemia.
2013 · Immunol Lett · RCR 0.3 · 10 citations
Show 7 more
- Antibodies to carbonic anhydrase in patients with connective tissue diseases: relationship with lung involvement.
2008 · Int J Immunopathol Pharmacol · RCR 0.3 · 12 citations - Low-avidity antibodies to carbonic anhydrase-I and -II in autoimmune chronic pancreatitis.
2002 · ScientificWorldJournal · RCR 0.3 · 9 citations - Proteomic surveillance of putative new autoantigens in thyroid orbitopathy.
2015 · Br J Ophthalmol · RCR 0.3 · 6 citations - Sera of patients with spontaneous tumour regression and elevated anti-CA I autoantibodies change the gene expression of ECM proteins.
2017 · J Cell Mol Med · RCR 0.3 · 6 citations - Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia.
2017 · Turk J Haematol · RCR 0.2 · 5 citations - Inhibitory Effect of Human Anti-CA I Autoantibodies and Development of Monoclonal Antibody mAb 2B8 Targeting Carbonic Anhydrase I.
2024 · Mediators Inflamm · RCR 0.2 · 1 citations - Detection of autoantibodies against carbonic anhydrase I and II in the plasma of patients with gastric cancer.
2017 · Cent Eur J Immunol · RCR 0.2 · 5 citations
Reference: B cellIEDB
1 publication
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.68
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.21
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- arylesterase activity
- carbonate dehydratase activity
- cyanamide hydratase activity
- hydro-lyase activity
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CA1 as an antibody target. Whether an autoantibody or antibody against CA1 could matter depends on whether native CA1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CA1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CA1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...